Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phyllis I Spuls

Showing results (61-70 of 126) with videos related to

Pageof 13
Sort By:
Expert Opinion on Drug Safety|August 10, 2022
Analysis and visualization of the course and burden over time of adverse drug reactions (ADRs) attributed to TNFα-inhibitors in patients with inflammatory rheumatic diseases (IRDs)Merel de Boer, Helen R Gosselt, Jurriaan Jansen, et al.
JAMA Dermatology|March 26, 2015
Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis: A Step Toward Personalized TreatmentStef P Menting, Emma Coussens, Mieke F Pouw, et al.
Journal of Clinical Medicine|April 26, 2025
A Quality Analysis of the Measurement Properties of the Clinician-Reported Outcome Measures for Vitiligo and of the Studies Assessing Them: A Systematic ReviewJolien Duponselle, Sandrine Herbelet, Liesbeth Delbaere, et al.
Clinical and Experimental Dermatology|April 24, 2025
How do atopic dermatitis trialists perceive the HOME Core Outcome Set? - a survey study from the HOME initiativeYuval Gilad, Eric L Simpson, Christian Apfelbacher, et al.
Journal of the American Academy of Dermatology|July 6, 2017
Discrepancy between the clinical and histopathologic diagnosis of soft tissue vascular malformationsSophie E R Horbach, Amalia M Utami, Lorine B Meijer-Jorna, et al.
JAMA Dermatology|October 12, 2022
Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) InitiativeYael A Leshem, Joanne R Chalmers, Christian Apfelbacher, et al.
Acta Dermato-Venereologica|November 25, 2016
Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET RegistriesPaula Davila-Seijo, Ignacio Garcia-Doval, Luigi Naldi, et al.
The British Journal of Dermatology|December 20, 2023
How to use the Harmonising Outcome Measures for Eczema Core Outcome Set for atopic dermatitis trials: a users' guideKim S Thomas, Laura Howells, Yael A Leshem, et al.
The British Journal of Dermatology|October 4, 2023
Harmonization of outcomes in epidermolysis bullosa: report of the Core Outcome Sets for Epidermolysis Bullosa (COSEB) kick-off meetingEva W H Korte, Phyllis I Spuls, Peter C van den Akker, et al.
Archives of Dermatology|February 17, 2010
Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasisLidian L A Lecluse, Rieke J B Driessen, Phyllis I Spuls, et al.
Pageof 13

Showing results (61-70 of 126) with videos related to

Sort By:
Pageof 13
Expert Opinion on Drug Safety|August 10, 2022
Analysis and visualization of the course and burden over time of adverse drug reactions (ADRs) attributed to TNFα-inhibitors in patients with inflammatory rheumatic diseases (IRDs)Merel de Boer, Helen R Gosselt, Jurriaan Jansen, et al.
JAMA Dermatology|March 26, 2015
Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis: A Step Toward Personalized TreatmentStef P Menting, Emma Coussens, Mieke F Pouw, et al.
Journal of Clinical Medicine|April 26, 2025
A Quality Analysis of the Measurement Properties of the Clinician-Reported Outcome Measures for Vitiligo and of the Studies Assessing Them: A Systematic ReviewJolien Duponselle, Sandrine Herbelet, Liesbeth Delbaere, et al.
Clinical and Experimental Dermatology|April 24, 2025
How do atopic dermatitis trialists perceive the HOME Core Outcome Set? - a survey study from the HOME initiativeYuval Gilad, Eric L Simpson, Christian Apfelbacher, et al.
Journal of the American Academy of Dermatology|July 6, 2017
Discrepancy between the clinical and histopathologic diagnosis of soft tissue vascular malformationsSophie E R Horbach, Amalia M Utami, Lorine B Meijer-Jorna, et al.
JAMA Dermatology|October 12, 2022
Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) InitiativeYael A Leshem, Joanne R Chalmers, Christian Apfelbacher, et al.
Acta Dermato-Venereologica|November 25, 2016
Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET RegistriesPaula Davila-Seijo, Ignacio Garcia-Doval, Luigi Naldi, et al.
The British Journal of Dermatology|December 20, 2023
How to use the Harmonising Outcome Measures for Eczema Core Outcome Set for atopic dermatitis trials: a users' guideKim S Thomas, Laura Howells, Yael A Leshem, et al.
The British Journal of Dermatology|October 4, 2023
Harmonization of outcomes in epidermolysis bullosa: report of the Core Outcome Sets for Epidermolysis Bullosa (COSEB) kick-off meetingEva W H Korte, Phyllis I Spuls, Peter C van den Akker, et al.
Archives of Dermatology|February 17, 2010
Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasisLidian L A Lecluse, Rieke J B Driessen, Phyllis I Spuls, et al.
Pageof 13